Get the Stockscreener App
8.01
1.60%
-0.13
Contineum Therapeutics Inc stock is traded at $8.01, with a volume of 662.48K.
It is down -1.60% in the last 24 hours and down -42.04% over the past month.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
See More
Previous Close:
$8.14
Open:
$8.25
24h Volume:
662.48K
Relative Volume:
0.37
Market Cap:
$301.35M
Revenue:
$50.00M
Net Income/Loss:
$-58.44M
P/E Ratio:
-4.102
EPS:
-1.9527
Net Cash Flow:
$-57.73M
1W Performance:
-39.23%
1M Performance:
-42.04%
6M Performance:
-39.55%
1Y Performance:
-34.98%
1-Day Range:
$7.72
$8.56
1-Week Range:
$7.96
$13.86
52-Week Range:
$7.72
$17.79
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
8.01 | 301.35M | 50.00M | -58.44M | -57.73M | -1.9527 |
VRTX
Vertex Pharmaceuticals Inc
|
508.71 | 128.94B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.63 | 95.27B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
799.98 | 82.36B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.28 | 53.79B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.53 | 42.37B | 5.76B | 514.49M | 1.10B | 4.4813 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy - Zacks Investment Research
13 Biotech Stocks to Watch: Candel (NASDAQ:CADL), Verastem (NASDAQ:VSTM), Surrozen (NASDAQ:SRZN) and Ten Other Nasdaq Biotech Stocks - kalkine.ca
A 4,170-share sale is proposed by Contineum Therapeutics (CTNM) officer Daniel Lorrain. - Stock Titan
Contineum fails in MDD; Definium’s LSD prospect nears NDA - bioworld.com
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Othe - Benzinga
Johnson & Johnson's depression drug trial misses its goal - Stock Titan
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com Canada
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com South Africa
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com India
Contineum Therapeutics CEO Stengone sells $41,141 in stock - Investing.com
Contineum Therapeutics CEO Stengone sells $41,141 in stock By Investing.com - Investing.com UK
Contineum (CTNM) CEO sells shares under preset plan - Stock Titan
Carmine Stengone to sell 2,500 Contineum (CTNM) shares - Stock Titan
Technical Reactions to CTNM Trends in Macro Strategies - Stock Traders Daily
Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs - RTTNews
RBC Capital Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Contineum Therapeutics (CTNM) Climbs 1.91% as Shares Hold Above Key SupportWyckoff Accumulation - vinanet.vn
Officer at Contineum (NASDAQ: CTNM) lines up new stock sale - Stock Titan
Contineum Therapeutics (CTNM) Climbs 1.91% as Shares Hold Above Key SupportWyckoff Accumulation - dars.gov.et
Contineum Therapeutics (CTNM) Climbs 1.91% as Shares Hold Above Key SupportValue Area Low - dars.gov.et
Behavioral Patterns of CTNM and Institutional Flows - Stock Traders Daily
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet - qz.com
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - The Chronicle-Journal
Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference - Yahoo Finance
Contineum Therapeutics schedules a Sept. 15 fireside chat at 5:35 p.m. - Stock Titan
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session - vinanet.vn
Contineum (CTNM) Chart: Records a 7.30% Increase to $17.19 for the Current Session; Chart View: the Current Price Sits Inside the Supplied Technical Range in the Available RecordVolatility Breakout Picks - siam.in
Balyasny Asset Management L.P. Expands Stake in Contineum Therap - GuruFocus
Contineum (CTNM) Results at a Glance: The Bottom-Line Figure Beats Its Comparison in Latest Trading; Closing Move - vinanet.vn
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating - marketscreener.com
Morgan Stanley Adjusts PT on Contineum Therapeutics to $18 From $16, Keeps Equalweight Rating - Moomoo
Contineum Therapeutics, Inc. Stock 12‑Month Price Target Raised to $23.14, Implies 63% Upside - TradingView
Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says - Yahoo Finance
Contineum Therapeutics (CTNM) Slides 7.25% to $14.19 — Testing Key Support After Sharp Sell-OffFair Value Gap - vinanet.vn
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Contineum Therapeutics (NASDAQ:CTNM) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Contineum Therapeutics (CTNM) Slides 7.25% to $14.19 — Testing Key Support After Sharp Sell-OffQuote Data - dars.gov.et
Contineum Therapeutics (NASDAQ:CTNM) Trading Down 4.9%What's Next? - marketbeat.com
Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Trading 6.8% HigherShould You Buy? - MarketBeat
These stocks are moving in today's pre-market session - ChartMill
CTNM Q2 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Share GainCFO Commentary Report - Vinanet
CTNM Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesGross Profit Margin - Vinanet
Contineum Therapeutics (CTNM) Pulls Back 3.66% to $14.49 as Support Level Comes into FocusComposite Profile - vinanet.vn
(CTNM) Risk Channels and Responsive Allocation - Stock Traders Daily
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Nigeria
Form 4 Contineum Therapeutics Inc For: 3 August By Investing.com - Investing.com Canada
Contineum Therapeutics CEO Stengone sells $40,029 of common stock By Investing.com - Investing.com Nigeria
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Contineum Therapeutics Inc Stock (CTNM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President |
Sep 08 '26 |
Sale |
16.46 |
2,500 |
41,142 |
17,217 |
| Stengone Carmine N. | CEO and President |
Sep 08 '26 |
Option Exercise |
1.01 |
2,500 |
2,525 |
19,717 |
| CARMINE STENGONE | Director |
Sep 08 '26 |
Proposed Sale |
16.70 |
2,500 |
41,750 |
0 |
| Daniel Lorrain | Officer |
Sep 01 '26 |
Proposed Sale |
16.24 |
9,520 |
154,605 |
0 |
| Stengone Carmine N. | CEO and President |
Aug 03 '26 |
Sale |
16.01 |
2,500 |
40,029 |
17,217 |
| CARMINE STENGONE | Director |
Aug 03 '26 |
Proposed Sale |
15.49 |
2,500 |
38,725 |
0 |
| Daniel Lorrain | Officer |
Aug 03 '26 |
Proposed Sale |
15.49 |
9,520 |
147,465 |
0 |
| Stengone Carmine N. | CEO and President |
Aug 03 '26 |
Option Exercise |
1.01 |
2,500 |
2,525 |
19,717 |
| Lorrain Daniel S. | Chief Scientific Officer |
Jul 09 '26 |
Sale |
16.00 |
25 |
400 |
135,202 |
| Lorrain Daniel S. | Chief Scientific Officer |
Jul 09 '26 |
Option Exercise |
1.01 |
25 |
25 |
135,227 |
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):